Prevention & lipidsCohort study
Epidemiological and Translational Study of Calprotectin and Atherosclerotic Cardiovascular Disease
- Prospective cohort study with translational in vitro study
- multiethnic
- population-based
Authors' conclusion
The findings suggest that calprotectin may serve as a mechanistically informed biomarker for ASCVD, independent of traditional and contemporary cardiovascular risk factors and biomarkers.
Study context
- Population
- Participants of phase 2 of the Dallas Heart Study, a multiethnic, population-based cohort
- Participants
- 2,412 participants
- Exposure
- Higher vs lower circulating calprotectin
- Outcome
- Atherosclerotic cardiovascular disease (ASCVD) events:
- First nonfatal MI
- Nonfatal stroke
- Coronary revascularization
- CV death
- Follow-up
- Median 8 years
Main finding
As reported in the abstract
ASCVD events per log increase in calprotectin · 8 years
Calprotectin (per log increase)Hazard ratio (95% CI)
unadjusted for risk factors
1.98(1.54–2.53)
adjusted for prior ASCVD and traditional risk factors
1.61(1.22–2.13)
further adjusted for hs-CRP, NT-proBNP and hs-cTnT
1.43(1.04–1.96)
Per log increase, as printed
Observational data: associations, not effects.
Further findings
CAC score
- Higher calprotectin correlated with higher CAC scores
- P < 0.001
In vitro mechanisms
- Calprotectin impaired coronary endothelial integrity, diminished nitric oxide production and fostered endothelial to mesenchymal transition
Original publication
Epidemiological and Translational Study of Calprotectin and Atherosclerotic Cardiovascular Disease. JAMA Cardiol. Published 1 July 2025. doi:10.1001/jamacardio.2025.0945
Summarised from the published abstract; every number is checked against it